BNP Paribas Financial Markets Invests $730,000 in Keros Therapeutics, Inc. (NASDAQ:KROS)

BNP Paribas Financial Markets acquired a new position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 46,110 shares of the company's stock, valued at approximately $730,000. BNP Paribas Financial Markets owned 0.11% of Keros Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in KROS. AlphaQuest LLC raised its position in shares of Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock worth $57,000 after acquiring an additional 2,964 shares in the last quarter. Virtus ETF Advisers LLC raised its position in shares of Keros Therapeutics by 107.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after acquiring an additional 1,998 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Keros Therapeutics in the 4th quarter worth approximately $90,000. Exchange Traded Concepts LLC bought a new position in shares of Keros Therapeutics in the 4th quarter worth approximately $99,000. Finally, CANADA LIFE ASSURANCE Co raised its position in shares of Keros Therapeutics by 207.8% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company's stock worth $116,000 after acquiring an additional 4,976 shares in the last quarter. Institutional investors own 71.56% of the company's stock.

Insiders Place Their Bets

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the company's stock in a transaction on Wednesday, April 9th. The stock was acquired at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the transaction, the insider now directly owns 4,392,737 shares of the company's stock, valued at approximately $44,498,425.81. This represents a 27.01% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 20.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Wedbush reaffirmed a "neutral" rating and set a $15.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Truist Financial lowered their price objective on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. HC Wainwright decreased their price target on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Wells Fargo & Company lowered their price target on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, February 27th. Finally, Scotiabank dropped their price objective on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research report on Monday, May 12th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $37.00.

Keros Therapeutics Stock Up 2.9%

NASDAQ:KROS traded up $0.41 on Friday, reaching $14.57. 581,064 shares of the company's stock traded hands, compared to its average volume of 843,309. The stock has a 50-day simple moving average of $12.70 and a 200-day simple moving average of $21.23. The firm has a market cap of $591.76 million, a PE ratio of -2.80 and a beta of 1.32. Keros Therapeutics, Inc. has a 12 month low of $9.12 and a 12 month high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $211.25 million for the quarter, compared to analysts' expectations of $84.62 million. During the same period in the previous year, the firm posted ($1.21) earnings per share. On average, equities analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.